Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
Treatment with rifampin-clarithromycin or moxifloxacin-clarithromycin for 8 weeks displayed promising bactericidal activity against Mycobacterium ulcerans in mice; none of the mice treated with rifampin-clarithromycin relapsed, whereas 59% of those treated with moxifloxacin-clarithromycin relapsed after treatment was stopped. The bactericidal and sterilizing activities of the five-times-weekly (5/7) administration of 5 mg of rifapentine/kg of body weight, either alone or in combination, were virtually identical to those of the corresponding regimens with 10 mg of rifampin/kg of body weight; however, because of the long half-life of rifapentine, accumulation of the drug after 5/7 administration is a concern. The bactericidal activity of 20 mg/kg rifapentine in monotherapy or 20 mg/kg rifapentine in combination with 150 mg/kg streptomycin or 200 mg/kg moxifloxacin administered twice weekly was as effective as the corresponding regimens containing 10 mg/kg rifampin administered 5/7, suggesting that Buruli ulcer might be treated with intermittently administered rifapentine-containing combinations.
Ji
Baohong
B
Bactériologie-Hygiène, Faculté de Médecine Pierre et Marie Curie, Universite Paris 6, 91 boulevard de l'Hôpital, 75634 Paris Cedex 13, France. baohong_ji@yahoo.com
Chauffour
Aurélie
A
Robert
Jérome
J
Jarlier
Vincent
V
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D051379:Mice; D008807:Mice, Inbred BALB C; D000077266:Moxifloxacin; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D019911:Mycobacterium ulcerans / Q000187:drug effects* / Q000254:growth & development; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D017291:Clarithromycin; D000077266:Moxifloxacin; D012293:Rifampin